{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Povero D"],"funding":["NIDDK NIH HHS","NIA NIH HHS","NCI NIH HHS","NIH HHS"],"pagination":["378-393"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11238876"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["79(2)"],"pubmed_abstract":["Background & aims
The prevalence of non-alcoholic steatohepatitis (NASH)-driven hepatocellular carcinoma (HCC) is rising rapidly, yet its underlying mechanisms remain unclear. Herein, we aim to determine the role of hypoxia-inducible lipid droplet associated protein (HILPDA)/hypoxia-inducible gene 2 (HIG2), a selective inhibitor of intracellular lipolysis, in NASH-driven HCC.Methods
The clinical significance of HILPDA was assessed in human NASH-driven HCC specimens by immunohistochemistry and transcriptomics analyses. The oncogenic effect of HILPDA was assessed in human HCC cells and in 3D epithelial spheroids upon exposure to free fatty acids and either normoxia or hypoxia. Lipidomics profiling of wild-type and HILPDA knockout HCC cells was assessed via shotgun and targete"],"journal":["Journal of hepatology"],"pubmed_title":["HILPDA promotes NASH-driven HCC development by restraining intracellular fatty acid flux in hypoxia."],"pmcid":["PMC11238876"],"funding_grant_id":["P30 AG013319","T32 DK007352","P30 CA015083","S10 OD028633","P30 DK084567","P30 AG044271"],"pubmed_authors":["Liu J","Razidlo GL","Johnson SM","Han X","Taner T","McMahon CE","Bao H","Lauer KP","Blake E","Chen Y","Petterson XT","Povero D","O'Brien DR","Graham RP","Pan M","Yu Y"],"additional_accession":[]},"is_claimable":false,"name":"HILPDA promotes NASH-driven HCC development by restraining intracellular fatty acid flux in hypoxia.","description":"Background & aims
The prevalence of non-alcoholic steatohepatitis (NASH)-driven hepatocellular carcinoma (HCC) is rising rapidly, yet its underlying mechanisms remain unclear. Herein, we aim to determine the role of hypoxia-inducible lipid droplet associated protein (HILPDA)/hypoxia-inducible gene 2 (HIG2), a selective inhibitor of intracellular lipolysis, in NASH-driven HCC.Methods
The clinical significance of HILPDA was assessed in human NASH-driven HCC specimens by immunohistochemistry and transcriptomics analyses. The oncogenic effect of HILPDA was assessed in human HCC cells and in 3D epithelial spheroids upon exposure to free fatty acids and either normoxia or hypoxia. Lipidomics profiling of wild-type and HILPDA knockout HCC cells was assessed via shotgun and targete","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Aug","modification":"2025-04-05T15:49:32.237Z","creation":"2025-04-05T15:49:32.237Z"},"accession":"S-EPMC11238876","cross_references":{"pubmed":["37061197"],"doi":["10.1016/j.jhep.2023.03.041"]}}